↓ Skip to main content

Dove Medical Press

Article Metrics

Multicenter, open-label, exploratory clinical trial with Rhodiola rosea extract in patients suffering from burnout symptoms

Overview of attention for article published in Neuropsychiatric Disease and Treatment, March 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#25 of 2,960)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
14 news outlets
blogs
1 blog
twitter
10 tweeters
facebook
23 Facebook pages
googleplus
1 Google+ user
reddit
1 Redditor
video
6 video uploaders

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
82 Mendeley
Title
Multicenter, open-label, exploratory clinical trial with <em>Rhodiola rosea</em> extract in patients suffering from burnout symptoms
Published in
Neuropsychiatric Disease and Treatment, March 2017
DOI 10.2147/ndt.s120113
Pubmed ID
Authors

Siegfried Kasper, Angelika Dienel

Abstract

This study is the first clinical trial aiming to explore the clinical outcomes in burnout patients treated with Rhodiola rosea. The reported capacity of R. rosea to strengthen the organism against stress and its good tolerability offer a promising approach in the treatment of stress-related burnout. The aim of the treatment was to increase stress resistance, thus addressing the source rather than the symptoms of the syndrome and preventing subsequent diseases associated with a history of burnout. The objective of the trial was to provide the exploratory data required for planning future randomized trials in burnout patients in order to investigate the clinical outcomes of treatment with R. rosea dry extract in this target group. The study was planned as an exploratory, open-label, multicenter, single-arm trial. A wide range of rating scales were assessed and evaluated in an exploratory data analysis to generate hypotheses regarding clinical courses and to provide a basis for the planning of subsequent studies. A total of 118 outpatients were enrolled. A daily dose of 400 mg R. rosea extract (WS(®) 1375, Rosalin) was administered over 12 weeks. Clinical outcomes were assessed by the German version of the Maslach Burnout Inventory, Burnout Screening Scales I and II, Sheehan Disability Scale, Perceived Stress Questionnaire, Number Connection Test, Multidimensional Mood State Questionnaire, Numerical Analogue Scales for different stress symptoms and impairment of sexual life, Patient Sexual Function Questionnaire, and the Clinical Global Impression Scales. The majority of the outcome measures showed clear improvement over time. Several parameters had already improved after 1 week of treatment and continued to improve further up to the end of the study. The incidence of adverse events was low with 0.015 events per observation day. The trial reported here was the first to investigate clinical outcomes in patients suffering from burnout symptoms when treated with R. rosea. During administration of the study drug over the course of 12 weeks, a wide range of outcome measures associated with the syndrome clearly improved. The results presented provide an encouraging basis for clinical trials further investigating the clinical outcomes of R. rosea extract in patients with the burnout syndrome.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 82 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 18%
Student > Master 13 16%
Researcher 13 16%
Other 6 7%
Student > Ph. D. Student 6 7%
Other 10 12%
Unknown 19 23%
Readers by discipline Count As %
Nursing and Health Professions 12 15%
Psychology 11 13%
Agricultural and Biological Sciences 9 11%
Medicine and Dentistry 8 10%
Biochemistry, Genetics and Molecular Biology 7 9%
Other 13 16%
Unknown 22 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 129. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 October 2022.
All research outputs
#263,392
of 22,512,774 outputs
Outputs from Neuropsychiatric Disease and Treatment
#25
of 2,960 outputs
Outputs of similar age
#6,133
of 279,840 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#1
of 78 outputs
Altmetric has tracked 22,512,774 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,960 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,840 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.